MiRXES logo

MiRXES

Biotechnology

51-200 Employees

3.5 (Glassdoor)

Unclaimed
Page has not been claimed by the company yet.

About MiRXES

MiRXES is a Singapore-headquartered biotechnology company whose mission is to deliver world-leading multi-cancer early detection. 

We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide.

Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers. 

We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey.

MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics.

Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases.

We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests in those countries which we have already gained access.

MiRXES Salaries

There are no salary data for MiRXES yet!

MiRXES Reviews

ADD A REVIEW

MiRXES Careers and Jobs (2)

MiRXES Culture

MiRXES has not added their culture yet, add them for FREE now!

MiRXES Employee Benefits

MiRXES has not added their benefits yet, add them for FREE now!

MiRXES Insights

Team Trends


Team Breakdown


Company

Frequently Asked Questions

MiRXES has 51-200 employees globally.

More about MiRXES: Salaries | Reviews | Jobs | Culture | Benefits
MiRXES is a Singapore-headquartered biotechnology company whose mission is to deliver world-leading multi-cancer early detection. 

We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide.

Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers. 

We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey.

MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics.

Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases.

We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests in those countries which we have already gained access.
There are 2 MiRXES jobs right now. Explore jobs like Full-Stack Software Engineer (Contract), Data Scientist and more.
According to anonymously submitted Glassdoor reviews, MiRXES has an overall rating of 3.5 out of 5 based on reviews left by employees. Find out more about salaries and benefits at MiRXES.